Ridner SH, Dietrich MS, Niermann K, Cmelak A, Mannion K, Murphy B. Preliminary development of a lymphedema symptom assessment scale for patients with head and neck cancer. Prevalence of secondary lymphedema in patients with head and neck cancer. doi: 10.1152/ajpcell.00535.2009.ĭeng J, Ridner SH, Dietrich MS, Wells N, Wallston KA, Sinard RJ, Cmelak AJ, Murphy BA. Radiation therapy causes loss of dermal lymphatic vessels and interferes with lymphatic function by TGF-beta1-mediated tissue fibrosis. In addition, preliminary data supports efficacy.įibrosis Head and neck cancer Lymphedema Pneumatic compression device.Īvraham T, Yan A, Zampell JC, Daluvoy SV, Haimovitz-Friedman A, Cordeiro AP, Mehrara BJ. This trial supports the safety and feasibility of the APCD for the treatment of secondary lymphedema in head and neck cancer patients. APCD use was associated with significant improvement in perceived ability to control lymphedema (p = 0.003) and visible external swelling (front view p < 0.001, right view p = 0.004, left p = 0.005), as well as less reported pain. Most patients used the APCD once per day, instead of the prescribed twice per day, citing time related factors as barriers to use. No device-related Serious Adverse Events were reported. In total, forty-three patients completed the study. Assessments were conducted at baseline and weeks 4 and 8.įorty-nine patients were enrolled (wait-list n = 25 intervention n = 24). Safety (CTCAE V4.0) and feasibility were primary endpoints secondary endpoints included efficacy measure by objective examination and patient reported outcomes (symptoms, quality of life, function), adherence barriers, and satisfaction. Participants were randomized to wait-list lymphedema self-management (standard of care) or lymphedema self-management plus the use of the APCD bid. A randomized, wait-list controlled trial was undertaken to evaluate an APCD in post-treatment HNC patients with lymphedema.Įligible patients had completed treatment for HNC, were disease free, and had lymphedema at enrollment. Advanced pneumatic compression devices (APCD) may address these issues. Cost and availability of trained therapists are known barriers to therapy. Standard treatment includes professionally administered complete decongestive therapy (CDT). Lymphedema associated with head and neck cancer (HNC) therapy causes adverse clinical outcomes.
0 Comments
Leave a Reply. |